ARCHIVES

Complaints Are “Astonishingly Far From Facts,” But NCI May Be Leaving Good Science Unfunded

This article is from The Cancer Letter archive.

Vol. 03 No. 17 | April 29, 1977

Download PDF Visit The Full Archive

Related Articles

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

January 14, 2005

Arthur Upton New Name In Director Race; Califano Meets With Prospects

May 6, 1977

Most Comprehensive Centers Score High; Few May Be In Trouble; Directors Back Program

May 19, 1978

In Setback For Generics, Court Overturns FDA.

November 9, 2001

Simmonds Succeeds Young As ACS President; Lame-Duck Session Unlikely To Approve Funding Bills

November 8, 2002

EARLY Breast Cancer Screening Bill Gains Traction Among Jewish Groups

June 19, 2009